CARCINOMA CERVIX- STUDY TO EVALUATE THE RESPONSE AND TOXICITY OF TELETHERAPY WITH CONCURRENT WEEKLY CARBOPLATIN VERSUS RADIATION THERAPY ALONE.

Abstract

Objective: To assess the clinical response and toxicity of concurrent treatment of external beam radiotherapy (EBRT) with carboplatin to external beam radiotherapy alone in cervical cancer. Total 40 patients dividedMethod and material: into two arms with 20 patients received EBRT with concurrent chemotherapy with weekly carboplatin 150mg and rest 20 patients received EBRT alone. Prescribed radiation dose to both the arms was 46 gray (Gy) in 20 fractions (#) in four weeks, 2.3Gy/# for ve days in a week. concomitant weekly carboplatin given to the patient 4 to 5 hours before the radiation. Complete response found in 15 patients (75%) in arm-A and 8Result: patients (40%)in arm-B along with productive gain in symptoms. Haematological toxicity and high-grade skin toxicity found in a greater number of patients in study arm. On the basis of study concluded that Patients with cervix cancer can be treated on schedule with concurrentConclusion: carboplatin with EBRT. This regimen is well tolerated and produces excellent response rates and acceptable toxicities.